Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 5.5% in the third quarter, Holdings Channel reports. The firm owned 1,103,326 shares of the biopharmaceutical company’s stock after acquiring an additional 57,125 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Sangamo Therapeutics were worth $956,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in SGMO. Renaissance Technologies LLC grew its position in shares of Sangamo Therapeutics by 58.8% during the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after acquiring an additional 1,528,600 shares during the last quarter. Marshall Wace LLP grew its position in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 207,476 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Sangamo Therapeutics by 55.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 38,850 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Sangamo Therapeutics during the second quarter worth about $67,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Sangamo Therapeutics during the second quarter worth about $89,000. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Trading Up 6.6 %

Shares of SGMO opened at $2.82 on Wednesday. Sangamo Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $3.18. The firm has a market capitalization of $588.38 million, a P/E ratio of -3.76 and a beta of 1.15. The firm’s 50-day moving average is $1.88 and its two-hundred day moving average is $1.10.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.07. The business had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter in the previous year, the company posted ($0.34) EPS. Analysts predict that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. StockNews.com raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, December 10th. Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, December 13th. Finally, Barclays increased their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.